US2020337990A1PendingUtilityA1

Hydrogel implants for lowering intraocular pressure

56
Assignee: OCULAR THERAPEUTIX INCPriority: Apr 25, 2019Filed: Apr 24, 2020Published: Oct 29, 2020
Est. expiryApr 25, 2039(~12.8 yrs left)· nominal 20-yr term from priority
Inventors:Michael GoldsteinArthur DriscollCharles D. BlizzardAnkita Desai
A61P 27/06A61P 27/02A61K 9/0024A61K 31/215A61K 47/34A61K 9/0051
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are sustained release biodegradable ocular hydrogel implants which are useful for lowering ocular pressure and for treating related conditions.

Claims

exact text as granted — not AI-modified
1 . A sustained release biodegradable intracameral hydrogel implant comprising travoprost and a polymer network. 
     
     
         2 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of polyethylene glycol (PEG) units. 
     
     
         3 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of multi-arm PEG units having from 2 to 10 arms. 
     
     
         4 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of multi-arm PEG units having from 4 to 10 arms. 
     
     
         5 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of multi-arm PEG units having from 4 to 8 arms. 
     
     
         6 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of multi-arm PEG units having 8 arms. 
     
     
         7 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of multi-arm PEG units having 4 arms. 
     
     
         8 . The hydrogel implant of  claim 1 , wherein the polymer network comprises a plurality of multi-arm PEG units having the formula: 
       
         
           
           
               
               
           
         
       
       wherein n represents an ethylene oxide repeating unit and the wavy lines represent the points of repeating units of the polymer network. 
     
     
         9 . The hydrogel implant of  claim 1 , wherein the polymer network is formed by reacting a plurality of polyethylene glycol (PEG) units selected from 4a20K PEG SAZ, 4a20K PEG SAP, 4a20K PEG SG, 4a20K PEG SS, 8a20K PEG SAZ, 8a20K PEG SAP, 8a20K PEG SG, 8a20K PEG SS with one or more PEG or Lysine based-amine groups selected from 4a20K PEG NH2, 8a20K PEG NH2, and trilysine, or a salt thereof. 
     
     
         10 . The hydrogel implant of  claim 1 , wherein the polymer network is formed by reacting 8a15K PEG-SAZ with trilysine or a salt thereof. 
     
     
         11 . The hydrogel implant of  claim 1 , wherein the polymer network is amorphous. 
     
     
         12 . The hydrogel implant of  claim 1 , wherein the polymer network is semi-crystalline. 
     
     
         13 . The hydrogel implant of  claim 1 , wherein the travoprost is homogenously dispersed within the polymer network. 
     
     
         14 . The hydrogel implant of  claim 1 , wherein the travoprost is delivered to the eye in a sustained manner for a period ranging from about 2 to about 8 months. 
     
     
         15 . The hydrogel implant of  claim 1 , wherein the travoprost is delivered to the eye in a sustained manner for a period ranging from about 3 to about 7 months. 
     
     
         16 . The hydrogel implant of  claim 1 , wherein the travoprost is delivered to the eye in a sustained manner for a period ranging from about 4 to about 6 months. 
     
     
         17 . The hydrogel implant of  claim 1 , wherein sustained release occurs in the aqueous humor. 
     
     
         18 . The hydrogel implant of  claim 1 , wherein the travoprost is microencapsulated. 
     
     
         19 . The hydrogel implant of  claim 1 , wherein the travoprost is microencapsulated with poly(lactic-co-glycolic acid) (PLGA) or poly(lactic acid) (PLA), or a combination thereof. 
     
     
         20 . The hydrogel implant of  claim 1 , wherein the travoprost is microencapsulated with PLA. 
     
     
         21 . The hydrogel implant of  claim 1 , wherein the polymer networks is conjugated to fluorescein. 
     
     
         22 . The hydrogel implant of  claim 1 , wherein the implant is designed for implantation near the corneal endothelial cells. 
     
     
         23 . The hydrogel implant of  claim 1 , wherein the implant is designed for implantation in the inferior iridocorneal angle. 
     
     
         24 . A method of lowering ocular pressure in a subject in need thereof comprising administering the hydrogel implant of  claim 1  to the eye of a subject. 
     
     
         25 . A method of treating ocular hypertension in a subject in need thereof comprising administering the hydrogel implant of  claim 1  to the eye of a subject. 
     
     
         26 . A method of treating glaucoma in a subject in need thereof comprising administering the hydrogel implant of  claim 1  to the eye of a subject. 
     
     
         27 . The method of  claim 23 , wherein the glaucoma is open angle glaucoma. 
     
     
         28 . The method of  claim 24 , wherein essentially no endothelial damage occurs following administration of a disclosed implant.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.